Loading research and source information…
Condition research
Explore selected type 2 diabetes studies of blood sugar control and cardiovascular risk. Some studies require specific background treatment or other health conditions.
MeSH D003924 · Also indexed as Diabetes Mellitus, Type 2
14 covered studies · 7 enrolling · 2 with posted results
Coverage grows through automated registry checks for relevant drug and biological treatment studies. This is not every trial or available treatment, and source checks do not establish clinical benefit. Enrollment and results counts exclude records whose source checks are overdue or under review. Listed ages are only part of eligibility; the study team must confirm eligibility and availability at your location.
Showing 9–14 of 14 matching studies · Page 2 of 2
Sorted by the registry’s latest update, not our check date. With the enrolling filter, locations must be marked recruiting; other views include sites that may be closed.
US: FDA approval not reviewed here
The registry reports completed. This is trial metadata, not an assessment of treatment benefit.
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Phase 3 · Completed
Registry enrollment: 962 participants
Study ages: 18 Years and older
Results posted Oct 16, 2026
Read trial record and resultsChecked Oct 27, 2026
US: FDA approval not reviewed here
The registry reports active not recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Ongoing, no longer enrolling
Planned enrollment: 207 participants
Study ages: 18 Years to 75 Years
No results-posting date in this record
Read trial record and resultsChecked Oct 28, 2026
The registry reports completed. This is trial metadata, not an assessment of treatment benefit.
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
US: FDA approval not reviewed here
The registry reports active not recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 3 · Ongoing, no longer enrolling
Planned enrollment: 537 participants
Study ages: 18 Years to 75 Years
No results-posting date in this record
Read trial record and resultsChecked Oct 28, 2026
US: FDA approval not reviewed here
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
Phase 3 · Enrolling participants
Planned enrollment: 600 participants
Study ages: 18 Years and older
Recruiting sites listed in: Canada, New Zealand, United States
No results-posting date in this record
Read trial record and resultsChecked Oct 27, 2026
US: FDA approval not reviewed here
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Phase 3 · Enrolling participants
Planned enrollment: 11,800 participants
Study ages: 18 Years and older
Recruiting sites listed in: Argentina, Australia, Austria, Belgium, Brazil and 46 more countries/territories (see details)
No results-posting date in this record
Read trial record and resultsChecked Oct 27, 2026
US: FDA approval not reviewed here
The registry reports completed. This is trial metadata, not an assessment of treatment benefit.
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
Phase 3 · Completed
Registry enrollment: 1,879 participants
Study ages: 18 Years and older
Results posted Feb 14, 2022
Read trial record and resultsChecked Oct 27, 2026
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
The registry reports completed. This is trial metadata, not an assessment of treatment benefit.
The registry reports completed. This is trial metadata, not an assessment of treatment benefit.
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.